Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment

Ina Giegling; Antonio Drago; Martin Schäfer; Annette M Hartmann; Thomas Sander; Mohammad Reza Toliat; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Dan Rujescu; Alessandro Serretti

doi:10.1007/s00213-010-2080-8

Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment

Ina Giegling, Antonio Drago, Martin Schäfer, Annette M Hartmann, Thomas Sander, Mohammad Reza Toliat, Hans-Jürgen Möller, Diana De Ronchi, Hans H Stassen, Dan Rujescu, Alessandro Serretti

Research output: Contribution to journal › Journal article › Research › peer-review

2 Citations (Scopus)

Abstract

RATIONALE: The antipsychotic pharmacological treatment effectiveness and side effects are at least partially driven by the genetic personal background.

OBJECTIVES: In the present study, 71 genetic variations located in 21 candidate genes were investigated as modulators of the haloperidol efficacy and side effects in a sample of 101 acutely ill psychotic patients.

METHODS: Patients were assessed at days 0, 7, 14, 21, and 28 (Positive and Negative Syndrome Scale (PANSS) test) and days 1, 3, 7, 14, 21, and 28 (UKU, BAS, and ESRS tests). Haloperidol plasma levels were measured at the same timepoints.

RESULTS: None of the 71 variations were associated with response to treatment or with incidence of side effects passed a multiple testing threshold. A marginal association was detected between two haplotypes within the signal transducer and activator of transcription 4 gene and PANSS positive and dopamine beta-hydroxylase with PANSS negative scores (p = 0.004 and p = 0.008, respectively).

CONCLUSIONS: In conclusion, no major association was observed between the investigated variations and the efficacy profile of haloperidol.

Original language	English
Journal	Psychopharmacology
Volume	214
Issue number	3
Pages (from-to)	719-28
Number of pages	10
ISSN	0033-3158
DOIs	https://doi.org/10.1007/s00213-010-2080-8
Publication status	Published - Apr 2011
Externally published	Yes

Keywords

Adult
Antipsychotic Agents/therapeutic use
Female
Gene Frequency
Genetic Variation
Genome-Wide Association Study/methods
Genotype
Haloperidol/blood
Humans
Male
Mental Disorders/blood
Middle Aged
Psychiatric Status Rating Scales
Time Factors

Access to Document

10.1007/s00213-010-2080-8

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{36d3d42ec9a64db19258666ec0d2f281,

title = "Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment",

abstract = "RATIONALE: The antipsychotic pharmacological treatment effectiveness and side effects are at least partially driven by the genetic personal background.OBJECTIVES: In the present study, 71 genetic variations located in 21 candidate genes were investigated as modulators of the haloperidol efficacy and side effects in a sample of 101 acutely ill psychotic patients.METHODS: Patients were assessed at days 0, 7, 14, 21, and 28 (Positive and Negative Syndrome Scale (PANSS) test) and days 1, 3, 7, 14, 21, and 28 (UKU, BAS, and ESRS tests). Haloperidol plasma levels were measured at the same timepoints.RESULTS: None of the 71 variations were associated with response to treatment or with incidence of side effects passed a multiple testing threshold. A marginal association was detected between two haplotypes within the signal transducer and activator of transcription 4 gene and PANSS positive and dopamine beta-hydroxylase with PANSS negative scores (p = 0.004 and p = 0.008, respectively).CONCLUSIONS: In conclusion, no major association was observed between the investigated variations and the efficacy profile of haloperidol.",

keywords = "Adult, Antipsychotic Agents/therapeutic use, Female, Gene Frequency, Genetic Variation, Genome-Wide Association Study/methods, Genotype, Haloperidol/blood, Humans, Male, Mental Disorders/blood, Middle Aged, Psychiatric Status Rating Scales, Time Factors",

author = "Ina Giegling and Antonio Drago and Martin Sch{\"a}fer and Hartmann, {Annette M} and Thomas Sander and Toliat, {Mohammad Reza} and Hans-J{\"u}rgen M{\"o}ller and {De Ronchi}, Diana and Stassen, {Hans H} and Dan Rujescu and Alessandro Serretti",

year = "2011",

month = apr,

doi = "10.1007/s00213-010-2080-8",

language = "English",

volume = "214",

pages = "719--28",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Physica-Verlag",

number = "3",

}

TY - JOUR

T1 - Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment

AU - Giegling, Ina

AU - Drago, Antonio

AU - Schäfer, Martin

AU - Hartmann, Annette M

AU - Sander, Thomas

AU - Toliat, Mohammad Reza

AU - Möller, Hans-Jürgen

AU - De Ronchi, Diana

AU - Stassen, Hans H

AU - Rujescu, Dan

AU - Serretti, Alessandro

PY - 2011/4

Y1 - 2011/4

N2 - RATIONALE: The antipsychotic pharmacological treatment effectiveness and side effects are at least partially driven by the genetic personal background.OBJECTIVES: In the present study, 71 genetic variations located in 21 candidate genes were investigated as modulators of the haloperidol efficacy and side effects in a sample of 101 acutely ill psychotic patients.METHODS: Patients were assessed at days 0, 7, 14, 21, and 28 (Positive and Negative Syndrome Scale (PANSS) test) and days 1, 3, 7, 14, 21, and 28 (UKU, BAS, and ESRS tests). Haloperidol plasma levels were measured at the same timepoints.RESULTS: None of the 71 variations were associated with response to treatment or with incidence of side effects passed a multiple testing threshold. A marginal association was detected between two haplotypes within the signal transducer and activator of transcription 4 gene and PANSS positive and dopamine beta-hydroxylase with PANSS negative scores (p = 0.004 and p = 0.008, respectively).CONCLUSIONS: In conclusion, no major association was observed between the investigated variations and the efficacy profile of haloperidol.

AB - RATIONALE: The antipsychotic pharmacological treatment effectiveness and side effects are at least partially driven by the genetic personal background.OBJECTIVES: In the present study, 71 genetic variations located in 21 candidate genes were investigated as modulators of the haloperidol efficacy and side effects in a sample of 101 acutely ill psychotic patients.METHODS: Patients were assessed at days 0, 7, 14, 21, and 28 (Positive and Negative Syndrome Scale (PANSS) test) and days 1, 3, 7, 14, 21, and 28 (UKU, BAS, and ESRS tests). Haloperidol plasma levels were measured at the same timepoints.RESULTS: None of the 71 variations were associated with response to treatment or with incidence of side effects passed a multiple testing threshold. A marginal association was detected between two haplotypes within the signal transducer and activator of transcription 4 gene and PANSS positive and dopamine beta-hydroxylase with PANSS negative scores (p = 0.004 and p = 0.008, respectively).CONCLUSIONS: In conclusion, no major association was observed between the investigated variations and the efficacy profile of haloperidol.

KW - Adult

KW - Antipsychotic Agents/therapeutic use

KW - Female

KW - Gene Frequency

KW - Genetic Variation

KW - Genome-Wide Association Study/methods

KW - Genotype

KW - Haloperidol/blood

KW - Humans

KW - Male

KW - Mental Disorders/blood

KW - Middle Aged

KW - Psychiatric Status Rating Scales

KW - Time Factors

U2 - 10.1007/s00213-010-2080-8

DO - 10.1007/s00213-010-2080-8

M3 - Journal article

C2 - 21079921

SN - 0033-3158

VL - 214

SP - 719

EP - 728

JO - Psychopharmacology

JF - Psychopharmacology

IS - 3

ER -

Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment

Abstract

Keywords

Access to Document

AUB Link

Fingerprint

Cite this